PMID- 11368361
OWN - NLM
STAT- MEDLINE
DCOM- 20010531
LR  - 20190915
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 15
IP  - 4
DP  - 2001 Apr
TI  - Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth 
      of BCR-ABL-positive acute lymphoblastic leukemia cells.
PG  - 590-4
AB  - By employing a new semi-quantitative assay system that includes co-culturing 
      leukemia cells with the mouse bone marrow-derived stromal cell line MS-5, we 
      examined the suppressive effect of a selective inhibitor of ABL tyrosine kinase, 
      STI571, on acute lymphoblastic leukemia (ALL) cells with BCR-ABL fusion. Leukemic 
      blast cells from eight patients with B-precursor ALL, including three patients 
      with BCR-ABL-positive ALL, were cultured on monolayers of MS-5 cells for 3 weeks 
      with or without addition of variable amounts of STI571. In all cases, cobblestone 
      areas (CAs) were formed, showing clear linear cell dose-dependent curves, 
      allowing quantitative assessment of blast cell growth. The progenitor frequencies 
      obtained by this direct CA-forming cell (CAFC) assay were equivalent to ALL 
      progenitor frequencies assessed by the standard limiting dilution assay. The 
      number of CAFCs ranged from 12.3 to 140.3/10(4) cells. In BCR-ABL-positive ALL 
      patients, CA-containing cells were examined by FISH, and all contained BCR-ABL 
      fusion genes. STI571 inhibited CA formation of BCR-ABL-positive ALL cells 
      virtually 100% at 0.1-1.0 micromol/l. None of the five BCR-ABL-negative ALL 
      patients showed this growth inhibition by STI571 at 0.1-1.0 micromol/l. Our 
      results indicate that STI571 selectively inhibits in vitro growth of 
      BCR-ABL-positive ALL cells.
FAU - Kawaguchi, Y
AU  - Kawaguchi Y
AD  - Department of Hematology, Nagasaki University School of Medicine, Japan.
FAU - Jinnai, I
AU  - Jinnai I
FAU - Nagai, K
AU  - Nagai K
FAU - Yagasaki, F
AU  - Yagasaki F
FAU - Yakata, Y
AU  - Yakata Y
FAU - Matsuo, T
AU  - Matsuo T
FAU - Kuriyama, K
AU  - Kuriyama K
FAU - Tomonaga, M
AU  - Tomonaga M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.2 (Proto-Oncogene Proteins c-abl)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Benzamides
MH  - Cell Division/drug effects
MH  - Female
MH  - Genes, abl
MH  - Humans
MH  - Imatinib Mesylate
MH  - Male
MH  - Mice
MH  - Piperazines/*pharmacology
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/pathology
MH  - Proto-Oncogene Proteins c-abl/*antagonists & inhibitors
MH  - Pyrimidines/*pharmacology
EDAT- 2001/05/23 10:00
MHDA- 2001/06/02 10:01
CRDT- 2001/05/23 10:00
PHST- 2001/05/23 10:00 [pubmed]
PHST- 2001/06/02 10:01 [medline]
PHST- 2001/05/23 10:00 [entrez]
AID - 10.1038/sj.leu.2402068 [doi]
PST - ppublish
SO  - Leukemia. 2001 Apr;15(4):590-4. doi: 10.1038/sj.leu.2402068.